Evaluation of a new rapid test for the detection of influenza A and B viruses and pandemic (H1N1) 2009 virus subtyping in respiratory samples

The emergence in 2009 of a novel influenza A (H1N1) virus was responsible for a pandemic outbreak of febrile respiratory infections worldwide (NSOIAVIT, 2009). During the first pandemic wave, specific real-time RT-PCR (rRT-PCR) assays were the reference methods for the detection of the pandemic (H1N1) 2009 influenza virus, leading to the overload of laboratory facilities due to the large number of clinical samples analysed (Duchamp et al., 2010). The re-emergence during winter 2011 of the pandemic (H1N1) 2009 virus highlighted the need for commercially available and readily performed influenza diagnostic tests capable of detecting and subtyping influenza A viral strains in respiratory samples. The previously reported sensitivity of commercially available rapid influenza antigen tests (RIATs) for pandemic (H1N1) 2009 virus was 11 to 80 %, and generally evaluated at around 60 % for clinical specimens (Drexler et al., 2009; Lee et al., 2010; Léveque et al., 2010; Louie et al., 2010).

Moreover, currently available RIATs are only able to type influenza A and B viruses, and do not specifically subtype the pandemic (H1N1) 2009 virus. The aim of this study was thus to assess the diagnostic performances, comparatively to the rRT-PCR assay, of a new RIAT, the ONE STEP influenza virus A/B/A(H1N1) pandemic rapid test (Standard Diagnostics; Bioline), which can detect the influenza viruses A and B, and subtype the pandemic (H1N1) 2009 in respiratory samples.

One hundred and six nasal swab specimens collected in September–December 2009 from patients of all age groups with influenza-like illness were retrospectively tested by RIAT. The Virocult system (Lakewood Biochemical), consisting of a rayon-budded swab and a transport tube of liquid virus transport medium, was used. Among the 106 clinical samples investigated, 56 had previously tested positive for pandemic (H1N1) 2009 influenza virus by H1 specific rRT-PCR assay (Duchamp et al., 2010). A total of 40 samples had previously tested positive for seasonal influenza A virus [10 (H1N1) and 20 (H3N2) influenza A virus specimens] or influenza B virus (10 specimens) by influenza A and B specific rRT-PCR assays developed by the French National Reference Centres for influenza viruses. Ten samples negative by rRT-PCR assays for influenza A and B viruses were also randomly selected.

Nasal swab samples were rapidly transported to the virology laboratory (Reims University Medical Centre, Reims, France) where 500 µl virus transport medium was added to the Virocult system, then each sample was divided between two sterile tubes. The first aliquot was prospectively tested for pandemic and seasonal influenza A and B viruses, while the second aliquot was used for the retrospective RIAT analysis. The ONE STEP influenza virus A/B/A(H1N1) pandemic rapid test is a chromatographic immunoassay with strips with immobilized mouse monoclonal anti-A(H1N1) pandemic haemagglutinin, anti-influenza A and anti-influenza B nucleoprotein antibodies. The RIAT was carried out according to the manufacturer’s instructions using 100 µl of the second aliquot stored at –80 °C.

Overall, from the 56 specimens positive for the pandemic (H1N1) 2009 influenza virus, the new rapid antigen test detected 22 positive samples, demonstrating a sensitivity of 39.3 % (range 26.5–52.1 %). This appeared to be lower than the sensitivity range 68.5–77 % recently reported in similar studies testing the same RIAT with the same sampling technique in comparison with a rRT-PCR assay (Choi et al., 2010; Kwon et al., 2011). A potential effect of the storage at –80 °C on the target antigens detected by the RIAT could not be ruled out, in particular in cases of low viral loads, as an explanation for the moderate sensitivity observed. No false-positive result for pandemic (H1N1) 2009 influenza virus detection was observed when seasonal influenza A and B virus-positive and -negative samples were tested with the new RIAT, indicating a specificity and a positive predictive value of 100 %. Thirty-four samples positive for the pandemic (H1N1) 2009 influenza virus by rRT-PCR assay were not detected by the RIAT, demonstrating a negative predictive value of 59.5 % (range 46.5–72.6 %). However, among these 34 samples, 4 were positive with the rapid antigen test for influenza A virus but were not identified as a pandemic variant, indicating that results positive for seasonal influenza A virus should be necessarily checked by a reference rRT-PCR assay for influenza A virus subtyping.

The viral load assessed in each influenza A-positive specimen using a rRT-PCR assay targeting the influenza A matrix (M) gene demonstrated that the positivity of the RIAT appeared to be significantly associated (Wilcoxon test) with the pandemic (H1N1) 2009 viral load levels in the clinical samples, since the median values were 5.5 × 10^3 ± 3.9 × 10^7 and 5.7 × 10^6 ± 6.9 × 10^6 M gene copies ml^-1 in RIAT positive and negative samples, respectively (P<10^-3) (Fig. 1). A receiver operating characteristics (ROC) analysis was also performed, showing an area under the curve of 0.804 (ROC value range 0.689–0.918) and confirming that the RIAT results were well correlated with the viral load quantified by the M rRT-PCR specific assay in the clinical samples. In this study, the smallest viral load detected in a clinical sample by the RIAT was 3.5 × 10^3 M gene copies ml^-1. Interestingly, RIAT performances appeared to be better for seasonal influenza A viruses than for pandemic (H1N1) 2009 virus diagnosis, since the median value of seasonal influenza A viral loads in clinical samples positive by
the RIAT was lower ($8.9 \times 10^3 \pm 2.4 \times 10^6$ M gene copies ml$^{-1}$) than for pandemic (H1N1) 2009 virus (Fig. 1). This could potentially explain the misidentification as seasonal influenza A virus of four samples positive for the pandemic variant. By contrast, Kwon et al. (2011), who developed this new RIAT in collaboration with the Standard Diagnostics Company, did not observe any difference in the detection limit between the haemagglutinin protein of A/Korea/01/2009 and the nucleoprotein of seasonal influenza A viruses when the kit was applied to clinical specimens.

In conclusion, our data showed a limited clinical value of this new rapid antigen test as a first-line screening strategy for nasopharyngeal samples obtained from (H1N1) 2009 virus suspect cases in daily virological diagnosis, since negative or positive results for seasonal influenza A virus should be necessarily checked by rRT-PCR assay for influenza A virus detection and subtyping.

Acknowledgements

We are indebted to the technicians who have prospectively and retrospectively tested the nasopharyngeal samples of the present study. This study was supported by a grant for clinical and virological research from the Medical University and School of Medicine of Reims (EA-4303/IFR53) and by the PHRC Gripmask (PHRC 2008, P070160). Fanny Renois is supported by an official grant from the French Army (Bourse DGA, Délégation Générale de l’Armement, Ministère de la Défense; topic – microbiology, infectious diseases; 2009–2012).

Nicolas Lévêque, Déborah Talmud, Fanny Renois, Coralie Barbe and Laurent Andréoletti

1Unité de Virologie Médicale et Moléculaire, Centre Hospitalier Universitaire, Reims, France
2IFR 53/EA-4303, Faculté de Médecine, Reims, France
3Coordination de la Recherche Clinique, Centre Hospitalier Universitaire, Reims, France

Correspondence: Nicolas Lévêque (nleveque@chu-reims.fr)


